Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 18:19:68-70.
doi: 10.1016/j.jdcr.2021.10.034. eCollection 2022 Jan.

Alopecia areata after mogamulizumab treatment

Neel S Raval  1 , Nora A Alexander  1 , Karlee De Monnin  1 , Christine C Yokoyama  1 , Neha Mehta-Shah  2 , Ilana S Rosman  1   3 , Amy C Musiek  1
Affiliations
Case Reports

Alopecia areata after mogamulizumab treatment

Neel S Raval et al. JAAD Case Rep. .
No abstract available

Keywords: AA, alopecia areata; CCR4, CC chemokine receptor 4; MF, mycosis fungoide; SS, Sézary syndrome; adverse event; alopecia areata; cutaneous t-cell lymphoma; mogamulizumab.

PubMed Disclaimer

Conflict of interest statement

Drs Musiek and Shah serve on the advisory board of Kyowa Kirin. Mr Raval, Ms Alexander, Ms Monnin, and Drs Yokoyama and Rosman have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
A, Well-demarcated patches of alopecia on the posterior aspect of the scalp. B, Progression to total scalp hair loss. C, Hair regrowth.
See this image and copyright information in PMC

References

    1. Kim Y.H., Bagot M., Pinter-Brown L., et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204. doi: 10.1016/S1470-2045(18)30379-6. - DOI - PubMed
    1. Chen L., Carson K.R., Staser K.W., et al. Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response. JAMA Dermatol. 2019;155(8):968–971. doi: 10.1001/jamadermatol.2019.0369. - DOI - PMC - PubMed
    1. Hirotsu K.E., Neal T.M., Khodadoust M.S., et al. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or Sézary syndrome. JAMA Dermatol. 2021;157(6):700–707. doi: 10.1001/jamadermatol.2021.0877. - DOI - PMC - PubMed
    1. Larocca C., Kupper T.S., LeBoeuf N.R. Mogamulizumab forecast: Clearer patients, with a slight chance of immune mayhem. Clin Cancer Res. 2019;25(24):7272–7274. doi: 10.1158/1078-0432.CCR-19-2742. - DOI - PMC - PubMed
    1. Kim K.H., Sim W.Y., Lew B.L. Nivolumab-induced alopecia areata: a case report and literature review. Ann Dermatol. 2021;33(3):284–288. doi: 10.5021/ad.2021.33.3.284. - DOI - PMC - PubMed

Publication types

LinkOut - more resources